Papillary Renal Cell Carcinoma Clinical Trials
25 clinical trials for Papillary Renal Cell Carcinoma across international registries, including 6 currently recruiting participants. Compare status, phase, eligibility criteria and locations.
- Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors — RECRUITING · PHASE2
- Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer — RECRUITING · PHASE2
- Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC) — RECRUITING · PHASE1
- A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors — RECRUITING · PHASE1
- An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy — RECRUITING · NA
- Real World Study of Effectiveness of Sunitinib or Sorafenib to Chinese Unresectable Locally Advanced or Metastatic PRCC — RECRUITING
- Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study — ACTIVE_NOT_RECRUITING · PHASE2
- Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC — ACTIVE_NOT_RECRUITING · PHASE2
- Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma — ACTIVE_NOT_RECRUITING · PHASE2
- Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing In Blood and Urine, The INQUIRE Study — COMPLETED
- Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC — ACTIVE_NOT_RECRUITING · PHASE3
- Study of Kidney Tumors in Younger Patients — COMPLETED
- Tumor-Derived Extracellular Vesicles for Noninvasive Molecular Classification of Kidney Cancer — NOT_YET_RECRUITING
- A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma — ACTIVE_NOT_RECRUITING · PHASE2
- Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer — COMPLETED · PHASE2
- Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer — ACTIVE_NOT_RECRUITING · PHASE1
- Multi-classifier System for Stratifying Stage III Papillary Renal Cell Carcinoma of Receiving Adjuvant Therapy — NOT_YET_RECRUITING · PHASE3
- Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer — WITHDRAWN · PHASE2
- Axitinib in1st Line Treatment for Patients With Advanced or Metastatic Papillary Renal Cell Carcinoma — COMPLETED · PHASE2
- A PHASE III, OPEN LABEL, RANDOMISED, 3-ARM, MULTI-CENTRE STUDY OF SAVOLITINIB PLUS DURVALUMAB VERSUS SUNITINIB AND DURVALUMAB MONOTHERAPY IN PARTICIPANTS WITH MET-DRIVEN, UNRESECTABLE AND LOCALLY ADVANCED OR METASTATIC PAPILLARY RENAL CELL CARCINOMA (PRCC) (SAMETA) — COMPLETED · PHASE3
- A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma — TERMINATED · PHASE1
- Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors — COMPLETED · PHASE2
- Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer — COMPLETED · PHASE1
- CASE SERIES OF CONTINUOUSLY-INFUSED AMPHOTERICIN-B AND FOLLOW-UP VORICONAZOLE THERAPY FOR SEVERE BLASTOMYCOSIS PULMONARY INFECTIONS — NOT_YET_RECRUITING
- Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer — TERMINATED · PHASE2
Refine this search